Drug intelligence / Profile preview

NEO Agent nanochains

Development stage: Preclinical
Lead developer: NeoIndicate
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

**NEO Agent nanochains** are preclinical, drug-loaded, PTPµ-targeted nanochains being developed by NeoIndicate for targeted treatment of invasive brain tumors, including pediatric glioma. The nanochains use a ligand that recognizes cancer-associated fragments of receptor-type tyrosine-protein phosphatase mu expressed in the tumor microenvironment while sparing intact PTPµ in normal tissue. Following tumor localization, an externally applied low-power radiofrequency field is intended to trigger local release of the encapsulated cytotoxic payload, potentially improving tumor exposure while limiting off-target drug delivery.

Other names: NEO Agent nanochainsNEO Agent nanoparticles

Targets

PTPRM

Beyond the preview

Go deeper on NEO Agent nanochains.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEO Agent nanochains.

Explore the full profile